Publication

Date Item Type Full Text Status

27 July 2026

Possible signals of ocular disorders associated with gabapentinoids: A three-arm study. (2026) Mya Murray, Amira Guirguis, Paul Deslandes, John Martin Corkery, Stefania Chiappini, Mariacristina Parravano and Fabrizio Schifano picture_as_pdf

30 October 2024

Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain. (2024) Chiara Montemitro, Alessio Mosca, Stefania Chiappini, Andrea Miuli, Fabrizio Schifano, Maria Josè Gordillo Montano, Cristina Merino Del Villar, Rita Allegretti, Carlotta Marrangone, Gilberto Di Petta, Domenico De Berardis, Mauro Pettorruso and Giovanni Martinotti

31 March 2024

3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18 F-FDG PET/CT Case Report. (2024) Maria Pepe, Marco Di Nicola, Fabrizio Cocciolillo, Stefania Chiappini, Giovanni Martinotti, Maria Lucia Calcagni and Gabriele Sani

6 March 2024

Shorter and Longer Antibiotic Durations for Respiratory Infections: To Fight Antimicrobial Resistance—A Retrospective Cross-Sectional Study in a Secondary Care Setting in the UK. (2024) Rasha Abdelsalam Elshenawy, Nkiruka Umaru and Zoe Aslanpour

18 August 2023

An update on psychoactive substances: Pharmacology and Toxicology issues. (2023) Stefania Chiappini and Fabrizio Schifano description

11 July 2023

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. (2023) Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi and Fabrizio Schifano

31 December 2022

Psilocybin for Depression: From Credibility to Feasibility, What’s Missing? (2022) Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini and Giuseppina Cantarella

27 May 2022

Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). (2022) Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, John M. Corkery, Giovanni Martinotti, Daniel R. Harris and Fabrizio Schifano

1 May 2022

A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. (2022) Stefania Chiappini, Rachel Vickers-Smith, Amira Guirguis, John Martin Corkery, Giovanni Martinotti and Fabrizio Schifano

26 July 2021

The psychonauts’ benzodiazepines; quantitative structure-activity relationship (QSAR) analysis and docking prediction of their biological activity. (2021) Valeria Catalani, Michelle Botha, John Martin Corkery, Amira Guirguis, Alessandro Vento, Norbert Scherbaum and Fabrizio Schifano description